Suven Life Sciences Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2019 • Manufacturing (CRAMS): 89.3% • Services (DDDSS): 7.3% • Unallocated: 3.5%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.05x)
- Institutional investors have been accumulating - FII+DII up 2.9pp
CONS
- Company is loss-making at the operating / net level
- Operating cash flow has been negative in recent years
- Interest coverage is weak at -904.2x - earnings barely cover interest
- Company has a low return on equity of -73.1% over last 3 years
- Company has a low return on capital employed of -65.3%
- Company's sales have been declining over the last five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SUVEN | 370.60 | 0.00 | 10471.77 | 0.00 | -127.61 | -147.70 | 3.57 | 90.70 | -78.71 | -3715.76 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 | |
| 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 139 | |
| Operating Profit | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -135 |
| OPM % | -737.11% | -768.30% | -1885.31% | -1266.95% | -3023.76% | -2031.52% | -2435.40% | -2980.95% | -2713.90% | -8670.65% | -3677.94% | -3330.92% | -3789.51% |
| 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before Tax | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | -0.00% | -0.00% | -0.00% | 3.63% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | 0 | 0 | 0 | 0 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| -1.10 | -0.58 | -1.92 | -1.22 | -1.29 | -2.27 | -1.79 | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 | -4.84 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 544 | 625 | 286 | 14 | 13 | 12 | 14 | 12 | 7 | 7 | 9 | |
| 414 | 427 | 300 | 130 | 93 | 134 | 139 | 140 | 172 | 291 | 378 | |
| Operating Profit | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -369 |
| OPM % | 23.75% | 31.70% | -5.04% | -802.77% | -593.11% | -1032.13% | -928.87% | -1093.51% | -2488.86% | -3996.73% | -4184.26% |
| 21 | 23 | 27 | 14 | 8 | 5 | 14 | 29 | 11 | 14 | 21 | |
| Interest | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 7 | 6 | 6 | 6 |
| Profit before Tax | 123 | 196 | 0 | -106 | -77 | -122 | -118 | -106 | -161 | -276 | -352 |
| Tax % | 29.16% | 36.74% | 15423.14% | 11.45% | 6.87% | -0.00% | -0.00% | 0.94% | -0.00% | -0.00% | -0.00% |
| Net Profit | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS | 6.84 | 9.72 | -1.88 | -7.40 | -5.67 | -9.05 | -6.63 | -4.82 | -7.37 | -10.48 | — |
| Dividend Payout % | 14.60% | 15.44% | -79.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- -35%
- 5 Years:
- -12%
- 3 Years:
- -19%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 7%
- 5 Years:
- 35%
- 3 Years:
- 76%
- 1 Year:
- 61%
RETURN ON EQUITY
- 10 Years:
- -51%
- 5 Years:
- -83%
- 3 Years:
- -73%
- Last Year:
- -102%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
| 654 | 755 | 226 | 131 | 58 | 82 | 354 | 248 | 87 | 408 | |
| 72 | 34 | 3 | 4 | 3 | 2 | 1 | 0 | 0 | 12 | |
| Trade Payables | 38 | 57 | 7 | 6 | 3 | 2 | 2 | 2 | 5 | 5 |
| 126 | 165 | 172 | 122 | 145 | 102 | 105 | 13 | 21 | 173 | |
| Total Liabilities | 903 | 1,023 | 421 | 275 | 222 | 202 | 483 | 285 | 135 | 624 |
| 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 | |
| Capital Work in Progress | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 | |
| 93 | 139 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | |
| Cash & Bank | 9 | 28 | 1 | 15 | 47 | 6 | 184 | 164 | 38 | 337 |
| 185 | 244 | 175 | 236 | 150 | 110 | 215 | 15 | 14 | 28 | |
| Total Assets | 903 | 1,023 | 421 | 275 | 222 | 202 | 483 | 285 | 135 | 624 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 144 | 113 | -38 | -132 | -95 | -127 | -115 | -115 | -154 | -301 | |
| Cash from Investing | -311 | -1 | 37 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from Financing | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| -232 | 17 | -11 | 14 | -5 | -4 | 32 | -22 | 0 | -7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)".
2026-08-25 - Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
2026-08-11 - Monitoring Agency Report for the quarter ended June 30, 2026
2026-08-07 - Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-06 - Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-31 - Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
2026-07-30 - Suven Life Sciences Limited has informed the Exchange about Letter to Shareholders regarding Annual Report 2025-26
2026-07-30 - Suven Life Sciences Limited has informed the Exchange about Business Responsibility and Sustainability Report for F.Y 2025-26
2026-07-30 - Suven Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 25, 2026
News
Recent coverage and analyst commentary for SUVEN
Loading news…
AI Stock Analyst
Suven Life Sciences Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account